Silo Pharma (NASDAQ:SILO) Trading Down 4.1% – Should You Sell?

Shares of Silo Pharma, Inc. (NASDAQ:SILO) were down 4.1% during trading on Monday . The stock traded as low as $2.92 and last traded at $3.07. 50,587 shares were traded during trading, a decline of 7% from the average session volume of 54,515 shares. The stock had previously closed at $3.20.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Silo Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Silo Pharma Stock Down 4.1%

The stock has a market cap of $3.84 million, a PE ratio of -0.70 and a beta of 0.71. The company has a fifty day moving average price of $5.22 and a 200 day moving average price of $5.53.

Silo Pharma (NASDAQ:SILO) last released its earnings results on Thursday, August 13th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.44). Silo Pharma had a negative net margin of 6,726.39% and a negative return on equity of 81.75%.

Institutional Trading of Silo Pharma

A number of institutional investors have recently made changes to their positions in the stock. AdvisorShares Investments LLC grew its holdings in shares of Silo Pharma by 10.8% in the first quarter. AdvisorShares Investments LLC now owns 663,965 shares of the company’s stock worth $239,000 after purchasing an additional 64,458 shares during the last quarter. DRW Securities LLC bought a new stake in Silo Pharma during the 4th quarter valued at $113,000. Geode Capital Management LLC boosted its position in Silo Pharma by 134.6% during the 4th quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock valued at $32,000 after buying an additional 53,309 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Silo Pharma during the 3rd quarter valued at $74,000. Hedge funds and other institutional investors own 5.58% of the company’s stock.

About Silo Pharma

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.